CUP AND HANDLE FORMING NEW PT 6.50+Price above 200 EMA. Bounced off-diagonal support. Bounced off 50% retracement. RSI Oversold. Confirmed trend reversal. Longby KM-Published 2
OVERSOLD, BOUNCED OFF TREND LINE, TESTED 50% RETRACEMENTOVERSOLD, BOUNCED OFF TREND LINE, TESTED 50% RETRACEMENT. Great price to buy in my opinion.Longby KM-Published 1
FDA gave breakthrough designation..Verastem announced it received FDA Breakthrough Therapy designation for VS-6766 with defactinib in recurrent low-grade serous ovarian cancer. If the flag holds, it looks like it could hit around $4.60. Considering adding to my position today. But probably will just hold with what I have. Longby jrothlanderPublished 0
VSTM Verastem Inc. - Is VSTM forming a W on a weekly chart?Is VSTM forming a W on a weekly chart? Decide for yourself. Resistance @2,7 @4,7 @10,30 and the sky is above 19 $ Good luck and happy trading everyone! Longby MarkLexisUpdated 3
VSTM Verastem - nice W forming - is this going to the sky soon? VSTM - nice W forming - is this going to the sky @ 19 $ and above ? Nice volume and start of steady uptrend. GOOD LUCK and enjoy investing Longby MarkLexisUpdated 3
Target in sight. $vstmLooks to me like an ascending triangle breakout. Unfortunately, the volume is fairly week, but we'll see where it takes us. I plan on taking profits in the yellow area. I might run a trailing stop loss when it enters that area and just let it run. $vstmLongby Ziomus90Published 4
$VSTM Verastem, Inc., Potential 20% UpsideVerastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.Longby DEXWireNewsPublished 3
$VSTM Bullish opportunity targeting double current price 1.48Bullish setup formed by 3 red daily candles closing at same price . this pattern can lead to significant price change and RSI signal positively .. bullish long more likely with stoploss at 1.25 (not far away) risk reward (-20% vs +100%). to be watched closely!! Longby WinnerTrader99Updated 1
VSTM - My first sample analysisSTOCH RSI - Borderline Overbought ADX and DI - DI + indicates uptrend - ADX starting to get up the mid line may indicate strong uptrend MACD - MACD and signal indicator have crossed and is going uptrend Bollinger bands - show close tunneling may, may signal uptrend REMARKS monitor buy signals + analyse fundamentals This is my first graph analysisby joseph_tejalPublished 220
Clear Short trade as the stock falls back into the 1.05 - 1.10 lShorted here on the break of 1.68 lots of stops taken out weak into next monthShortby opcondourUpdated 3
Easy - LONG Verastem! Chart, Technicals, Cash, Upcoming news.... These guys have a COVID trial that starts June 30th and we have yet to see an 8-k or PR for it. This is a great time to go long and setup for it....We are looking to finally establish 2.05 support...there are a LOT of shorts to come running home if we do so... First time we will test with a healthier MACD and CMF on the week....STOCH and RSI look great as well.... not a ton of downside risk - if you want, let go if we break the 200day - but other than that this one is way too easy right now. ENJOY THE FIRE WORKS <3 Longby GK-TradesPublished 226
VERASTEM INCNASDAQ:VSTM Here you go, friends, good instrument to long If we form a pressure under the level, we'll go up well, don't miss it. Longby AllexMlUpdated 447
VSTM trendVSTM seems to have great potential up to $3 a share, and in the long trend it is below the average range. This past quarter earnings is better than the previous quarter.Longby shannontrades658Published 4
RSI, MACD indicators are starting to look good?The RSI is near the bottom of its range. The MACD, though in a steep decline is showing that the indicators are closing in. With this stock having a history of sharp gains and losses it could be a really nice set up for some very sharp gains. Also note the huge gap down it took April 27 as there could be a nice gap fill. Note. I am very new so do not make trades off of my advice. Hopefully someone with some experience will say a few things! Be Blessed! I am in with a 2.00 averageLongby ksteinke3Published 4
Could this be a H&S play?Expcting $VSTM to go up to atleast $2.4 as with H&S pay as shown below. Long with Ave 1.88.... by sunnybPublished 113
A cute stock to buy and hold for couple days Seems like it reached the bottom of the Bollinger band and resistance of the trendline. Also, RSI is low enough. After a little possible drop, it is very likely to go up sharply for a couple of days.Longby sevkisentunaPublished 6
$VSTM Verastem upside targets Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA. Longby DEXWireNewsPublished 2213
Long SetupAccumulation below 1.40 think this lasts another month of bouncing off 1.40. Can't ignore this setup as it looks similar to 2017. Long and will add. S/L below 1.16. Bio's can quickly turn down off dilution or study results so manage appropriately.Longby JohnStiversPublished 3